Cancer & Disease Research
The National Institutes of Health launches the Symptom Science Center
The National Institutes of Health, National Institute of Nursing Research (NIH NINR) launched the Symptom Science Center on June 27th, 2019 at the NIH Campus in Bethesda, MD. This event, attended by over 500 individuals, marks a momentous occasion for both clinical and translational multidisciplinary research. Read More
A convergence of technologies, revolutionizing next-generation sequencing
A new, powerful combination of biochips and next-generation sequencing (NGS) is capable of solving unique and important biological problems, such as single-cell, rare-cell or rare-molecule analysis, which NGS can't do on its own. Read More
Purchasing products: Experiences with scientists and suppliers
Recently, we asked over 900 members of the SAB to tell us more about how they purchase products through life science suppliers, and the factors that influence their selection of supplier. Read More
Customer service and technical support: From your perspective
Over 700 members of the SAB recently took part in a survey regarding their experiences with customer service and technical support through life science suppliers. We thought you’d like to know a little more about some of the results from this project, to understand how some of the research we conduct with your help ends up! Read More
New study shows the importance of ethnicity in genomic variants associated with disease
27 new genomic variants associated with conditions such as blood pressure, type 2 diabetes, cigarette use and chronic kidney disease in diverse populations have been identified by the National Institutes of Health. Data from nearly 50,000 participants from various ethnic backgrounds were tested to determine how genomic variants influence risk to certain diseases. Read More
Liquid Biopsies Offer a Viable Alternative to Tissue Biopsies
Liquid biopsies are a set of minimally invasive diagnostic methods that analyze tumor-derived materials that can be found circulating in biological fluids, to provide information for the diagnosis, treatment, and monitoring of cancer. While tissue biopsies and imaging techniques remain the current standards of care in the diagnosis of solid tumors, they have risks and limitations and limitations, some of which can be overcome by the use of liquid biopsy in clinical oncology, as an alternative or complementary technique to the current standards of care. Read More
Experimental Therapeutic Treatment for Deadly Tick-Borne Virus
Findings of the treatment of Bourbon disease in mice were published on June 13 in PLOS Pathogens. Only a few cases of the newly discovered Bourbon virus have been reported, and two of them ended in death, partly because no specific treatments are available for the tick-borne illness. Now, researchers at Washington University School of Medicine in St. Louis have identified an experimental antiviral drug, often used to treat the flu, that cures mice infected with the potentially lethal virus. Read More
Global Collaboration Launched for Large-Scale DNA Study Exploring Connection Between Genetics and Disease
A new partnership was announced between Intermountain Healthcare and deCODE Genetics to collaborate on the largest DNA mapping effort undertaken in the US from a single population. The initiative, called the HerediGene: Population Study, will analyze the complete DNA of 500,000 participants. Read More
Evolution of the Pap Smear
This May we recognized Georgios Papanikolaou for his revolutionary research in cervical cancer screening and prevention — you might even recall seeing him on the Google doodle on May 13th! Read More
UK Scientists Weigh In on Brexit and Laboratory Spending - Science Advisory Board Insights
The long road to a resolution of the Brexit situation appeared to be nearing an end earlier this year, with the deadline set for March 29 to finalize how Britain would exit the EU. A “hard” Brexit, the case if no EU-Britain agreement is reached, would remove Britain from the EU’s single market among other consequences. A “soft” exit would result in Britain remaining part of the single market, but not an EU member. With a government stalemate in Britain, the EU agreed to extend the deadline until October 31, though a deal may come sooner. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter